Where Will Madrigal Pharmaceuticals Be in 3 Years? [Yahoo! Finance]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Yahoo! Finance
Its first medicine just hit the market, sales are due to start rolling in, and there aren't any other companies that can slow it down -- for now, that is. By mid-2027, its shareholders will probably be richer than they are today. But beyond that time point, all bets are off, and in fact, it's very possible for things to start getting more difficult for Madrigal a bit sooner. Here's what could happen and why. It'll be growing, and likely quickly As of today, there's one big reason why Madrigal should be seeing revenue flow to its top line -- and eventually earnings -- over the coming three years. Its medicine, Rezdiffra, is the only approved treatment for the liver disease called metabolic-associated steatohepatitis (MASH, formerly known as NASH). While Rezdiffra is only indicated to treat patients with moderate-to-severe fibrosis (scarring) of the liver, the company plans to continue with its research and development (R&D) activities to test its helpfulness in the context of m
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- FDA grants clearance to Sonic Incytes' VDFF for liver health assessment [Yahoo! Finance]Yahoo! Finance
- FDA Grants 510(k) Clearance to Sonic Incytes' Velacur® Determined Fat Fraction (VDFF), a breakthrough for patients with MASLD and MASH [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance